Retinal Cavernous Hemangioma: Diagnosis and Care
Understanding Retinal Cavernous Hemangioma
A retinal cavernous hemangioma is a benign vascular hamartoma, which means it is a noncancerous growth made up of abnormal blood vessels within the retina. The retina is the thin layer of tissue at the back of the eye that detects light and sends visual signals to the brain. These growths consist of clusters of dilated, thin-walled blood vessel sacs in the inner layers of the retina.
When viewed during an eye examination, these clusters create a distinctive appearance often described as looking like a 'cluster of grapes.' The condition is present from birth in most cases, though it may not be discovered until later in life. These lesions typically appear in only one eye and tend to remain stable in size over time.
Retinal cavernous hemangiomas have unique characteristics that set them apart from other blood vessel abnormalities in the eye. The blood vessel walls in these growths have a normal, intact lining. This lining does not allow fluid or proteins to leak into the surrounding retinal tissue. This is different from many other retinal vascular conditions where leakage is a primary concern.
Blood flows slowly through the dilated channels within the hemangioma. This slow flow creates a distinctive pattern on fluorescein angiography (a diagnostic imaging test that uses dye to photograph blood vessels in the retina). The delayed filling of dye without leakage helps retina specialists distinguish this condition from other vascular growths.
Most cases of retinal cavernous hemangioma occur sporadically, meaning they develop without a known family history. However, some cases follow an autosomal dominant inheritance pattern. In this pattern, a parent with the condition has a one-in-two chance of passing it to each child (National Library of Medicine, 2023). These familial forms are linked to mutations in cerebral cavernous malformation genes, particularly CCM1/KRIT.
When the condition runs in families, it may involve more than just the retina. Familial forms are typically bilateral, meaning both eyes are affected. They are associated with similar blood vessel growths in the brain and skin (Retina Society Review, 2016). Genetic testing for the three known CCM genes can help confirm hereditary cases and guide further evaluation.
Who Is Affected and Risk Factors
Retinal cavernous hemangioma is a rare condition. A review of 96 documented cases from 1934 to 2015 found that more than 90 percent of reported cases occurred in white individuals (Retina Society Review, 2016). The condition shows a slight female predominance, with a female-to-male ratio of roughly 3 to 2. The average age at diagnosis is around 23 years (Specialty Vision Review, 2023).
The condition can be found across all age groups since it is typically present from birth. Many patients are diagnosed incidentally during routine eye examinations conducted for other reasons.
The most significant risk factor is having a family history of retinal, cerebral, or cutaneous (skin) cavernomas. Mutations in CCM genes, particularly CCM1/KRIT, follow an autosomal dominant inheritance pattern. These mutations increase the likelihood of developing growths in multiple organs.
Familial forms carry additional risks because they are often associated with cavernous hemangiomas in the central nervous system. Cerebral cavernous hemangiomas are three times more common in the upper part of the brain compared to the lower part (National Library of Medicine, 2023). Family members of affected individuals should discuss screening options with their healthcare providers.
In rare cases, retinal cavernous hemangiomas may be associated with other systemic conditions. Familial forms can involve the central nervous system and skin, creating a pattern of multi-organ involvement. In very rare instances, the condition may be associated with Sturge-Weber syndrome, a condition that affects blood vessel development.
Because of these potential associations, a multidisciplinary approach is increasingly recognized as the standard of care. This may involve retina specialists, neurologists, and genetic counselors for patients with known familial forms or systemic features.
Signs and Symptoms
The majority of patients with retinal cavernous hemangioma experience no symptoms. Because the blood vessel walls remain intact and do not leak, the surrounding retinal tissue is usually unaffected. Many patients maintain good visual function throughout their lives. The condition is most often discovered during a dilated eye examination performed for unrelated reasons.
Symptoms develop when the hemangioma affects a critical part of the retina or causes bleeding. If the lesion is located in or near the macula (the central part of the retina responsible for detailed vision), patients may notice blurred or distorted vision. Some patients develop an epiretinal membrane (a thin layer of scar-like tissue on the retinal surface) that can lead to visual changes.
A small percentage of patients may experience vitreous hemorrhage (bleeding into the gel-filled space inside the eye) at some point (AAO, 2024). When this occurs, patients may notice a sudden increase in floaters, hazy or cloudy vision, or a reddish tint to their sight.
Certain symptoms require immediate medical attention. See a retina specialist or go to the emergency room right away if you experience any of the following:
- Sudden onset of new floaters or a large number of dark spots in your vision
- Flashing lights in one or both eyes
- A shadow or curtain appearing over part of your visual field
- Sudden, significant blurring or loss of vision in one eye
These symptoms could indicate new bleeding or other serious complications that need prompt evaluation and care.
Diagnosis and Testing
A retina specialist typically identifies a cavernous hemangioma during a comprehensive dilated eye examination. Using specialized instruments, the specialist can see the characteristic cluster of dark, grape-like vascular sacs on the retinal surface. The appearance alone is often highly suggestive of the diagnosis.
The specialist will evaluate the location of the lesion relative to the macula and optic nerve. They will also assess whether any hemorrhage is present and document the size for future comparison.
Fluorescein angiography is a key diagnostic tool for confirming retinal cavernous hemangioma. During this test, a special dye is injected into a vein in the arm. As the dye circulates through the retinal blood vessels, a series of photographs are taken. In cavernous hemangiomas, the dye fills the vascular sacs slowly and does not leak. This pattern of delayed filling without leakage is a hallmark of the condition.
Spectral-domain optical coherence tomography, commonly called SD-OCT, creates detailed cross-sectional images of the retina. This noninvasive scan allows retina specialists to visualize the multiloculated (multi-chambered) vascular spaces within the hemangioma. OCT can also detect associated epiretinal membranes and subtle changes in the surrounding retinal structure.
When a retinal cavernous hemangioma is diagnosed, a brain MRI (magnetic resonance imaging) scan is typically recommended. This checks for associated cerebral cavernomas. It is especially important in patients with a family history of the condition or when bilateral lesions are present.
Genetic testing for the three known CCM genes may be advised in familial cases. Identifying a specific gene mutation can help guide screening for other family members. It also informs decisions about monitoring for brain or skin involvement.
Treatment Options
The large majority of retinal cavernous hemangiomas require no active treatment. Because these lesions are benign, rarely grow, and typically do not leak, periodic observation is the standard approach. A retina specialist will usually recommend follow-up examinations every 6 to 12 months. These visits monitor the lesion for changes in size, new hemorrhage, or complications like epiretinal membranes.
During these visits, the specialist may repeat imaging tests such as OCT to track the condition over time. Most patients who are monitored this way maintain stable vision for many years.
For patients who develop recurrent vitreous hemorrhage or other complications, several treatment options are available. Laser photocoagulation (thermal laser applied to the retina) can seal off abnormal blood vessels and reduce the risk of further bleeding. Photodynamic therapy, or PDT (a treatment using a light-activated drug), is another option for symptomatic lesions.
The choice between these treatments depends on the size, location, and behavior of the hemangioma. A retina specialist will recommend the most appropriate approach for each individual case.
Vitrectomy (a surgery to remove the gel inside the eye) may be performed when persistent vitreous hemorrhage affects vision and does not clear on its own. During this procedure, the vitreous gel containing blood is removed and replaced with a clear solution.
Additional options for complicated cases include cryotherapy (freezing treatment) and plaque radiotherapy (a small radioactive device placed near the tumor). More recently, proton beam therapy has shown promising results in achieving tumor regression and preventing hemorrhagic recurrences. These advanced treatments are typically reserved for cases that do not respond to standard measures.
What to Expect
The long-term outlook for most patients with retinal cavernous hemangioma is favorable. The majority of lesions remain stable in size and do not cause vision problems. Most patients maintain good visual function throughout their lives with appropriate monitoring. Even when vitreous hemorrhage occurs, the bleeding often resolves on its own or responds well to treatment.
Patients with lesions located away from the macula generally have an excellent visual prognosis. Those with macular involvement or recurrent hemorrhage may experience some degree of visual change, but treatment can help manage these complications.
Regular follow-up with a retina specialist is important even when no symptoms are present. These visits allow the specialist to detect any changes early and intervene promptly if needed. Patients with familial forms may need additional monitoring, including periodic brain MRI scans.
Patients should keep all scheduled appointments and report any new visual symptoms between visits. Maintaining open communication with the retina specialist ensures the best possible care.
For patients with familial forms or known systemic associations, coordinated care among multiple specialists is important. This may include a retina specialist for eye monitoring, a neurologist for brain cavernoma surveillance, and a genetic counselor for family planning and screening. This team-based approach helps ensure all aspects of the condition are managed comprehensively.
Living With Retinal Cavernous Hemangioma
Most patients with retinal cavernous hemangioma can carry on with normal daily activities without restrictions. Since the condition is typically asymptomatic and stable, it does not interfere with work, driving, reading, or exercise in most cases. A retina specialist can provide personalized guidance about activity considerations based on the lesion.
Being diagnosed with any eye condition can cause concern, even when the condition is benign. Understanding that retinal cavernous hemangioma is noncancerous and usually stable can provide significant reassurance. Patients who feel anxious may benefit from discussing their concerns with their retina specialist.
For patients with familial forms, knowing about the genetic component may raise questions about family health. Genetic counseling can help address these concerns and guide decisions about family screening.
Patients can play an active role by monitoring their vision between appointments. An Amsler grid (a simple chart with a grid pattern used to detect changes in central vision) can be a useful tool. By checking one eye at a time and noting any new distortion, blurriness, or missing areas, patients can detect potential changes early.
Keeping a record of any visual changes, even minor ones, can be helpful during follow-up visits. Early detection of new symptoms allows for timely evaluation and treatment if needed.
When to See a Retina Specialist
Anyone diagnosed with a retinal cavernous hemangioma should be under the care of a retina specialist for ongoing monitoring. Optometrists and primary care doctors can identify the condition during routine examinations and make appropriate referrals. Regular dilated eye examinations are important for detecting changes over time.
If a retinal cavernous hemangioma is found along with a family history of cavernous hemangiomas in the eyes, brain, or skin, family members should be evaluated. First-degree relatives (parents, siblings, and children) should consider both an eye examination and brain MRI. Genetic testing can help clarify the risk for other family members.
While most patients with this condition do not experience emergencies, it is important to know the warning signs that require prompt care. See a retina specialist or go to the emergency room immediately if you notice a sudden increase in floaters, flashes of light, a curtain or shadow moving across your vision, or sudden vision loss in one eye. These symptoms could indicate vitreous hemorrhage or another serious complication.
Questions and Answers
No. Retinal cavernous hemangiomas are benign (noncancerous) vascular growths. They do not transform into cancer. The cells lining these blood vessel clusters are normal endothelial cells, and the growths do not invade surrounding tissue or spread to other parts of the body. While the word 'tumor' may sound alarming, these lesions behave very differently from malignant tumors.
Most patients with retinal cavernous hemangioma do not need any treatment beyond regular monitoring. Because these lesions are typically stable and do not leak, observation every 6 to 12 months is the standard approach. Treatment is only considered when complications such as recurrent vitreous hemorrhage or macular involvement affect vision. If treatment becomes necessary, several effective options are available, including laser therapy, vitrectomy, and proton beam therapy.
If the hemangioma is an isolated, sporadic finding in one eye, family testing may not be necessary. However, if the condition appears in both eyes or if there is a family history of cavernous hemangiomas, family screening is recommended. First-degree relatives should consider a dilated eye examination and possibly a brain MRI. Genetic testing for CCM gene mutations can help determine whether the condition is hereditary.
A retina specialist will typically recommend follow-up examinations every 6 to 12 months after the initial diagnosis. The exact schedule depends on the size and location of the hemangioma, whether complications are present, and whether the condition is sporadic or familial. Between visits, patients should monitor their vision at home and contact their retina specialist promptly if new symptoms develop.
In most sporadic cases, retinal cavernous hemangioma affects only one eye. However, familial forms of the condition are more likely to involve both eyes. When bilateral lesions are found, further evaluation for systemic associations is typically recommended. This includes brain MRI and genetic testing. A retina specialist can determine the appropriate monitoring plan based on whether one or both eyes are involved.